Casi Pharmaceuticals (CASI) announced the appointment of David Cory as CEO and a member of the board of directors. Wei-Wu He will step down as the CEO and will remain as executive chairman of the board of directors. Most recently, Cory was CEO and director of LIB Therapeutics which completed Phase 3 registration-enabling trials for its lead cardiovascular disease program and filed for regulatory approval.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off